AbbVie (ABBV) Other Non-Current Assets (2012 - 2026)

AbbVie has disclosed Other Non-Current Assets across 15 years of filings, most recently posting $10.5 billion for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 14.62% year-over-year to $10.5 billion; the TTM figure through Mar 2026 stood at $10.5 billion (up 14.62% YoY), while the FY2025 annual figure was $10.7 billion, up 17.27% from the prior year.
• Other Non-Current Assets declined to $10.5 billion in Q1 2026, from $10.7 billion in the prior quarter.
• Over the last five years, Other Non-Current Assets for ABBV reached as high as $10.7 billion in Q4 2025 and fell as low as $5.0 billion in Q2 2022.
• The 5-year median for Other Non-Current Assets is $8.5 billion (2023), against an average of $7.9 billion.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets soared 56.33% — and 2025, when it rose 1.38%.
• A 5-year view of Other Non-Current Assets shows it stood at $5.6 billion in 2022, then surged by 52.81% to $8.5 billion in 2023, then gained by 7.39% to $9.1 billion in 2024, then advanced by 17.27% to $10.7 billion in 2025, then slipped by 1.73% to $10.5 billion in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $10.5 billion, $10.7 billion, and $9.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.